Zacks Research Has Negative Outlook of Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Zacks Research lowered their Q2 2026 EPS estimates for Surmodics in a report issued on Wednesday, May 21st. Zacks Research analyst D. Dey now expects that the company will post earnings of $0.02 per share for the quarter, down from their previous forecast of $0.04. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' FY2027 earnings at $0.31 EPS.

A number of other research firms have also commented on SRDX. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th. Finally, Wall Street Zen initiated coverage on Surmodics in a research note on Monday, February 3rd. They issued a "hold" rating for the company. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $43.00.

Surmodics Trading Down 1.6%

Shares of NASDAQ SRDX traded down $0.46 during trading hours on Friday, hitting $28.70. The company's stock had a trading volume of 89,263 shares, compared to its average volume of 279,724. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The stock has a market cap of $410.38 million, a price-to-earnings ratio of -28.42 and a beta of 1.32. Surmodics has a 12 month low of $26.00 and a 12 month high of $42.44. The business has a 50-day simple moving average of $28.84 and a 200-day simple moving average of $33.83.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The firm had revenue of $28.09 million during the quarter, compared to the consensus estimate of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Institutional Trading of Surmodics

Large investors have recently bought and sold shares of the company. Gabelli Funds LLC raised its position in shares of Surmodics by 16.3% in the 1st quarter. Gabelli Funds LLC now owns 395,509 shares of the company's stock worth $12,075,000 after acquiring an additional 55,550 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in Surmodics in the fourth quarter worth $11,880,000. Hsbc Holdings PLC raised its holdings in Surmodics by 4.8% in the first quarter. Hsbc Holdings PLC now owns 267,042 shares of the company's stock worth $8,252,000 after purchasing an additional 12,344 shares in the last quarter. Gardner Lewis Asset Management L P lifted its position in Surmodics by 23.5% during the fourth quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock valued at $10,410,000 after buying an additional 49,944 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Surmodics by 71.6% during the 1st quarter. Millennium Management LLC now owns 206,487 shares of the company's stock valued at $6,304,000 after buying an additional 86,143 shares in the last quarter. 96.63% of the stock is owned by institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).